United Drug is a healthcare services provider. The Company has four segments: Pharma Wholesale, Supply Chain Services, Medical and Scientific, and Contract Sales and Marketing Services.United Drug provides commercialisation solutions to international healthcare companies. We specialise in supply chain, packaging, sales and marketing, medical and regulatory services. We operate in five major international markets, and employ over 7,000 people around the world

http://www.united-drug.com/home/

16 Oct Berenberg 515.00 Hold

Trading Statement
RNS
RNS Number : 7010N
UDG Healthcare Public Limited Co.
02 February 2016

UDG HEALTHCARE PLC



FIRST QUARTER TRADING UPDATE



Strong Start to the Year and Full Year Guidance Issued





2 February 2016: UDG Healthcare plc ("the Group"), a leading international provider of healthcare services, issues the following trading update covering the period from 1 October to 31 December 2015. The company will hold its Annual General Meeting in Dublin at 12.00pm today.



Quarter to 31 December 2015



Group



The Group has made a strong start to the financial year with trading for the quarter to 31 December 2015 well ahead of the prior year.



Ashfield Commercial & Medical Services



Trading across the Ashfield division has again been strong, resulting in operating profit for the division being ahead of the same period last year.



Operating profit growth was particularly positive within the US and European commercial businesses, whilst the UK commercial business demonstrated a lower growth profile in its more mature market. The healthcare communications business has again delivered good profit growth in the period.



Sharp Packaging Services



The positive trading momentum in the Sharp US business has continued during the first quarter with operating profits significantly ahead of the prior year. Progress in Sharp Europe continues to be incremental as we re-align the business for future profitability.

The capacity expansion programme at our Allentown facility in Pennsylvania remains on target to open in April 2016, with the first phase of packaging suites becoming operational in the second half of 2016.



Aquilant



Operating profits in Aquilant were slightly ahead of the same quarter last year.



Disposal Update



The disposal of the United Drug Supply Chain and MASTA businesses was approved by shareholders on 13 October 2015. The actual timing of disposal remains subject to competition authority clearance which we continue to expect by June 2016.



United Drug has traded satisfactorily during the quarter.



CEO Transition



Further to our CEO transition announcement on 18 September 2015, the Group announces that the handover has been brought forward and that Liam FitzGerald will now step down as CEO at the AGM to be held later today and Brendan McAtamney will take over as CEO. Mr FitzGerald will continue as a non-executive director as planned until September 2016 and will continue to support the transition of CEO responsibilities and our strategic development efforts on a consulting basis.



Outlook



Based on the underlying trading performance to date, we expect constant currency adjusted diluted earnings per share (EPS)1 for the continuing Group2 for the year to 30 September 2016 to be between 6% and 8% ahead of last year's continuing Group EPS of 27.4c.



The Group currently reports in euro and its profits benefit from any strengthening of the US dollar and pound sterling exchange rates as over 90% of the continuing Group's profits are now in these currencies. The average FY15 exchange rates were €1 = £0.74 and $1.15.



The Group also reiterates its dividend guidance for FY16, whereby we expect to continue our long history of dividend growth. As a result, the dividend per share for FY16 should increase over the FY15 dividend of 11c per share.



The Group expects to deliver a good underlying cashflow performance for the year. Modest debt levels and the net proceeds from the United Drug disposal leave the Group in a strong position to support its ongoing growth and expansion, both organically and through acquisition.





1 Before the amortisation of acquired intangible assets, exceptional items and non-recurring costs associated with acquisition and divestment activity.

2 All Group businesses excluding the United Drug Supply Chain and MASTA businesses whose disposal was announced on 18 September 2015.

2 Feb Goodbody N/A Buy
2 Feb Jefferies... 630.00 Buy

Broker Forecast - Berenberg issues a broker note on UDG Healthcare PLC
Berenberg today upgrades its investment rating on UDG Healthcare PLC (LON:UDG) to buy (from hold) and raised its price target to 585p (from 550p). Story provided by StockMarketWire.com

questor-share-tip-udg-healthcare-war-chest-can-accelerate-growth/

3 Jun Berenberg 655.00 Buy

Q3 trading statement

4 Aug Davy Research N/A Outperform
4 Aug Goodbody N/A Buy
4 Aug Numis 675.00 Add

10:30 27/10/2016
Broker Forecast - Liberum Capital issues a broker note on UDG Healthcare PLC
Liberum Capital today initiates coverage of UDG Healthcare PLC (LON:UDG) with a buy investment rating and price target of 750p. Story provided by StockMarketWire.com

Broker Forecast - Berenberg issues a broker note on UDG Healthcare PLC
BFN
Berenberg today reaffirms its buy investment rating on UDG Healthcare PLC (LON:UDG) and raised its price target to 720p (from 700p).

Story provided by StockMarketWire.com

Final results

Financial highlights (continuing Group only)
·    Diluted earnings per share1 (EPS) from continuing operations increased by 8% (9% on a constant currency basis).
·    Revenue growth of 3% to €943.1m. Underlying revenue2 up 7%.
·    Operating profit1 growth of 8% (9% on a constant currency basis) to €104.2 million.
·    Operating margin1 increased from 10.5% to 11.1%. Net operating margin3 increased from 12.2% to 12.6%.
·    Profit before tax1 up 10% (11% on a constant currency basis).
·    Proposed 5% increase in final dividend to 8.50c per share, yielding a full year dividend of 11.55c per share.
·    The Group has net cash of €128.3m at 30 September 2016.
·    Return on capital employed (ROCE) for 2016 was 13.7%, up from 13.5% in 2015.
 
Strategic & operating highlights
·    Disposal of the United Drug Supply Chain businesses and MASTA completed on 1 April 2016 resulting in a net profit on disposal of €132.1m.  
·     Completed the acquisition of Pegasus in April 2016, and STEM post year end. Both acquisitions are an excellent strategic fit for Ashfield, with good growth prospects and a higher margin profile.
·     Ashfield's operating profit increased by 7% (underlying growth2 of 9%), driven by positive underlying growth2 in both Ashfield Commercial & Clinical and Ashfield Communications.
·    Sharp's operating profit increased by 16% (underlying growth2 of 12%) driven by continued growth in the US commercial packaging business.
·   Sharp completed the build and fit out of its new packaging facility in Allentown, Pennsylvania increasing US commercial packaging capacity by approximately 30%. 
·     Aquilant's performance negatively impacted by adverse currency movements with underlying2 operating profit €0.2 million down.

13:20 15/12/2016
Broker Forecast - Jefferies International issues a broker note on UDG Healthcare PLC
Jefferies International today reaffirms its buy investment rating on UDG Healthcare PLC (LON:UDG) and raised its price target to 750p (from 745p). Story provided by StockMarketWire.com

1st Quarter Trading Update

RNS


RNS Number : 1585W

UDG Healthcare Public Limited Co.

07 February 2017




UDG HEALTHCARE PLC



FIRST QUARTER TRADING UPDATE



Good start to the year and full year guidance issued



7 February 2017:



UDG Healthcare plc ("the Group"), a leading international provider of healthcare services, issues the following trading update covering the period from 1 October to 31 December 2016. The company will hold its Annual General Meeting in Dublin at 12.00pm today.



Quarter to 31 December 2016



Group



The Group has made a good start to the financial year with operating profits for the quarter to 31 December 2016 well ahead of the same quarter last year. This performance has been driven by continued good underlying growth and the impact of acquisitions. As a result of the fall in the value of Sterling, reported profit growth was moderated by the translation of our Sterling profits into US Dollars.



Ashfield



Trading is well ahead of the same quarter last year, with good underlying growth supplemented by acquisitions. STEM was acquired in October 2016 and has performed in line with expectations.



Within the Ashfield Commercial & Clinical business, operating profit growth was strongest in the US, as the business ramps up activity on contract wins from 2016. The Ashfield communications business continues to perform well with underlying profit ahead of the same quarter last year.



Sharp



Divisional operating profits during the quarter were moderately ahead of a strong comparable quarter last year.



The Sharp US commercial packaging business continues to increase activity levels within its recently expanded facility in Allentown, Pennsylvania. The business also continues to increase its engagement with clients in preparation for the serialisation of prescription products from November 2017. Both factors are expected to have a more material benefit on performance in the second half of the year.



Sharp Europe remains focused on converting its improved business development pipeline into new business activity. This pipeline is mainly in the biotech focused Belgian facility.





Aquilant



Aquilant's underlying operating profits were in line with the same quarter last year.



Board Appointment



The Board is pleased to announce the appointment of Mr. Myles Lee as a non-executive director of the Company with effect from 1 April 2017. Mr. Lee was Group Chief Executive of CRH plc, a FTSE100 and Fortune 500 company, prior to retiring in December 2013.



Group Outlook & Development



With effect from 1 October 2016, the Group now reports its financial results in US Dollars.



Based on the Group's good trading performance during the first quarter of the financial year, the Group expects constant currency adjusted diluted earnings per share (EPS)1 for the year to 30 September 2017 to be between 13% and 16% ahead of last year's continuing Group EPS of US$ 31.8c (Euro: 28.6c).



The average FY16 exchange rates were US$1 = £0.704 and €0.90. Based on the current prevailing exchange rates, the Group is likely to face a foreign exchange headwind on the translation of Sterling profits in FY17.



The Group remains in a net cash position, leaving the business well positioned to continue its corporate development activities, which should serve to complement its continued underlying profit growth.



1 Before the amortisation of acquired intangible assets, transaction costs and exceptional items



Date for Interim Results



The Group will issue its interim results for the six months to 31 March 2017 on Tuesday 23 May 2017.

15:20 04/04/2017
Broker Forecast - Numis issues a broker note on UDG Healthcare PLC
Numis today downgrades its investment rating on UDG Healthcare PLC (LON:UDG) to hold (from add) and left its price target at 730p. Story provided by StockMarketWire.com
12:30 04/04/2017
Broker Forecast - Stifel issues a broker note on UDG Healthcare PLC
Stifel today reaffirms its hold investment rating on UDG Healthcare PLC (LON:UDG) and raised its price target to 650p (from 620p). Story provided by StockMarketWire.com

13:00 07/02/2018
Broker Forecast - N+1 Singer issues a broker note on UDG Healthcare PLC
N+1 Singer today reaffirms its hold investment rating on UDG Healthcare PLC (LON:UDG) and set its price target at 813p. Story provided by StockMarketWire.com Broker Forecasts data provided by www.sharesmagazine.co.uk
08:30 07/02/2018
Broker Forecast - Liberum Capital issues a broker note on UDG Healthcare PLC
Liberum Capital today upgrades its investment rating on UDG Healthcare PLC (LON:UDG) to buy (from hold) and left its price target at 884p. Story provided by StockMarketWire.com Broker Forecasts data provided by www.sharesmagazine.co.uk

Notice of Interim Results
RNS
RNS Number : 6463M
UDG Healthcare Public Limited Co.
01 May 2018


1 May 2018
UDG Healthcare plc
Notice of Interim Results

UDG Healthcare plc ("the Group"), a leading international healthcare services provider, will issue its interim results for the half year ended 31 March 2018 at 07:00am (BST) on Tuesday 22 May 2018.

Interim report